Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus upgraded shares of Aimmune Therapeutics to a positive rating in a report on Monday, September 16th. Wedbush restated a buy rating on shares of Aimmune Therapeutics in a report on Thursday, October 31st. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a sell rating to a hold rating in a report on Monday, October 21st. ValuEngine upgraded shares of Aimmune Therapeutics from a buy rating to a strong-buy rating in a report on Monday, November 4th. Finally, Royal Bank of Canada decreased their price target on shares of Aimmune Therapeutics to $50.00 and set an outperform rating for the company in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $43.11.
NASDAQ:AIMT traded up $1.11 during trading hours on Wednesday, hitting $29.48. 626,600 shares of the stock traded hands, compared to its average volume of 717,952. The company has a current ratio of 5.80, a quick ratio of 5.80 and a debt-to-equity ratio of 0.24. Aimmune Therapeutics has a fifty-two week low of $16.95 and a fifty-two week high of $31.83. The firm has a 50 day moving average price of $24.90 and a 200 day moving average price of $21.36. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -8.03 and a beta of -0.03.
In related news, CFO Eric Bjerkholt acquired 1,550 shares of the business’s stock in a transaction dated Wednesday, September 18th. The stock was acquired at an average price of $22.57 per share, with a total value of $34,983.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.75% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Aperio Group LLC acquired a new position in shares of Aimmune Therapeutics during the second quarter valued at about $76,000. Vanguard Group Inc. raised its position in shares of Aimmune Therapeutics by 4.6% during the second quarter. Vanguard Group Inc. now owns 3,706,394 shares of the biotechnology company’s stock valued at $77,167,000 after buying an additional 164,038 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Aimmune Therapeutics by 11.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 5,246,604 shares of the biotechnology company’s stock valued at $109,234,000 after buying an additional 535,072 shares during the last quarter. TD Asset Management Inc. raised its position in shares of Aimmune Therapeutics by 5.7% during the second quarter. TD Asset Management Inc. now owns 100,076 shares of the biotechnology company’s stock valued at $2,084,000 after buying an additional 5,400 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Aimmune Therapeutics during the second quarter valued at about $221,000. 78.41% of the stock is owned by institutional investors and hedge funds.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Featured Article: Support Level
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.